How much do you know about the epidemiology and treatment of advanced and metastatic skin cancer? Test your knowledge with our latest quiz.
ERK pathway inhibition causes tumor shrinkage of metastatic skin cancer tumors harboring activating BRAF mutations. Of 76 patients in the study, 44 (58%) experienced tumor responses on dabrafenib plus trametinib, with a median time to progression of 5.6 months (95% CI, 5.3–7.4 months).
A.Vemurafenib, encorafenib or vemurafenib
Encorafenib with or without binimetinib demonstrated better efficacy than vemurafenib, and encorafenib plus binimetinib "appears to have an improved tolerability profile" compared with encorafenib or vemurafenib, the study authors reported.
Obesity appears to be associated with improved PFS and OS compared with patients with normal BMI, particularly among men treated with targeted therapy and immunotherapy, according to a study published in the Lancet Oncology in February.
Active duty and military veteran populations experience elevated skin cancer risk, with the highest rates occurring in the US Air Force, according to a recent review of published studies.